Loading
A phase 3 trial of Ivosidenib and Azacitidine in acute myeloid leukaemia, run by Servier Affaires Médicales, now recruiting.
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. is a phase 3 interventional study registered as NCT05907057 by Servier Affaires Médicales, with 245 participants planned, started 2023-06-14 and due to reach its primary completion in 2027-10-15. Interventions recorded: Ivosidenib 500mg Oral Tablet and Azacitidine.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares IDH inhibitors, Servier, Ivosidenib, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag pipeline.
Shares Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia, Cytotoxic chemotherapy and the tag pipeline.
Shares Acute myeloid leukaemia in older or unfit patients, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Acute myeloid leukaemia and the tag pipeline.